CureVac NV (WBO:CVAC) Change In Payables And Accrued Expense : €-50.37 Mil (TTM As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Change In Payables And Accrued Expense?

CureVac NV's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2023 was €-9.93 Mil. It means CureVac NV's Accounts Payable & Accrued Expense declined by €9.93 Mil from Jun. 2023 to Sep. 2023 .

CureVac NV's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2022 was €-96.19 Mil. It means CureVac NV's Accounts Payable & Accrued Expense declined by €96.19 Mil from Dec. 2021 to Dec. 2022 .

CureVac NV Change In Payables And Accrued Expense Historical Data

The historical data trend for CureVac NV's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Change In Payables And Accrued Expense Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Payables And Accrued Expense

9.40

-9.58

620.31

179.32

-96.19

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial														-2.71	35.56	-67.67	-8.33	-9.93

CureVac NV Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-50.37 Mil.

CureVac NV Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of CureVac NV's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.